



ARTICLE TYPE: Research Article

Unlocking the Secrets of Effective Sustained-Release Valsartan Tablets

Dr. Debashis Purohit^{1*}, Dr. Amit Kumar Nayak¹, Mahendra Kumar Sahu¹ and Deependra Soni¹

¹MATS School of Pharmacy, MATS University, Arang-Kharora Highway, Gullu, Aarang, Raipur, Chhattisgarh, Pin-493441, India

Corresponding Author:

Dr. Debashis Purohit

How to cite:

Purohit, D., Nayak, A. K., Sahu, M. K., & Soni, D. (2024). Unlocking the secrets of effective sustained-release valsartan tablets. *IFR Journal of Medicine and Surgery*, 1(2), 13-21. <https://doi.org/10.70146/msv01i02.002>

DOI: 10.70146/msv01i02.002

Received: 04-09-2024

Accepted: 20-09-2024

Revised: 01-10-2024

Published: 10-10-2024

Abstract: Background: Valsartan is mostly recognized for the antihypertensive effects that it has. Biodegradable and harmless in their natural state, natural polymers also have fewer negative side effects. In contrast to synthetic polymers, it does not harm the environment and may be used without risk to humans. The focus of this effort was on developing sustained-release tablets of valsartan by the use of natural polymers such as guar gum and pectin. At the moment, the formulation of sustained-release tablets that include a matrix system is receiving a significant amount of attention. Formulation of sustained-release tablets of valsartan was accomplished by the use of the direct compression technique. The produced tablets were put through a variety of various pre-formulation tests before being put through *in-vitro* dissolving testing using a USP-III dissolution device. At 37°C, dissolution experiments of a variety of formulations were analyzed for 24 hours. The produced formulations, each of which had a different concentration of polymers (1:0.5, 1:1, and 1:1.5) respectively, were analyzed for a variety of physicochemical properties, and the findings of an *in-vitro* dissolution investigation showed that FG3 demonstrated superior drug release. As a result, the findings of the research indicate that FG3 might be an excellent option for the production of sustained release tablets of valsartan using natural polymers.

Keywords: Sustained release, Matrix tablets, Valsartan, Guar gum, Pectin, *In-vitro*, polymer, FG3.

INTRODUCTION

When it comes to several different medications, the fundamental objective of treatment is to attain a steady state blood or tissue level that is both effective in terms of therapeutic also nontoxic over a considerable amount of time [1-5]. It is generally recommended to use a S.R. dosage form because of the following reasons: less variation of the drug in the body with good patient compliance; increase in impregnability margin of administration of drug; good drug absorption with less frequency of dosing; decrease in G.I.T. irritation due to the drug's local and systemic side effects; and good drug absorption with less frequency of dosing [6-10]. The accomplishment of the objective is significantly reliant on the conception of an appropriate shape. In the recent historical context, the C.R. notion has been getting a growing amount of attention towards the inability and toxicity of pharmacological substances when they are applied or allocated by standard methods of drug distribution [11-18]. As a

result, medications that are taken in the form of injectables, ointments, tablets, or capsules tend to cause fluctuations in the concentration of the drug in the systemic circulation, which results in ineffective toxicity and poor efficacy [19-25]. Hydrophilic polymeric matrix systems are used extensively in controlled drug delivery because of the reason as they simplify the process of achieving a good drug release profile, are economical, and have widespread support from the FDA[26-30]. A controlled release drug delivery system is not only meant to slow down the rate at which the medication is distributed into the body, but it is also responsible for the repeatability and predictability of the rate at which drug substances are distributed [6]. Controlled release dosage forms may allow some degree of control over the time character of drug release in the body, as well as the spatial pattern of drug release, or both. A efficient and prolonged prolonged delivery of therapeutically effective dosages, localization of therapy, and patient comfortness are some of the important benefits that a sustained release dosage form may bring to us. These benefits can be appreciated when taking into consideration the factors of efficient and prolonged delivery [31-35]. The frequency of dosage may be reduced with the aid of an effectively designed S.R. drug delivery system, which in turn helps to keep drug concentrations stable in the systemic circulation. When the concentration of the medication drops below the minimum effective dosage level as a consequence of the fluctuations that occur in traditional drug administration, the outcome is a yield period that has a weaker therapeutic impact. By using a S.R. drug delivery system, it is possible to keep the drug concentration within a very narrow therapeutic range. This will result in a reduction in the severity of side effects and a reduction in the number of episodes [36-40]. In certain instances, the bioavailability of medication molecules to diseased tissue cells is controlled by a series of pharmacokinetics processes called release'-absorption, distribution, metabolism, and elimination. This sequence is responsible for the bioavailability of drug molecules. As a consequence of these processes, the medicine is not available to the cells of the target tissue in an effective manner [41-45].

The benefits of using formulations with continuous release [46-50]

- Strong ability to condense when patient
- Increased therapeutic efficacy
- Affordable from a financial standpoint
- Less variations in dosage • Correct place of action

Disadvantages of sustained release formulations include the possibility of overdosing, an increase in cost, and the possibility that an improper formulation might lead to an excessive dose or an inaccurate drug release.

Variables relating to pharmacodynamics and pharmacokinetics. The rate of absorption, the distribution of the medication, the biological half-life, and the metabolic conversion of the drug are all factors that are involved in the sustained release dosage form.

In formulations for sustained release, the function of the matrix system [52-55] makes use of hydrophobic as well as hydrophilic polymers in order to prolong the tablet's longevity and to extend the amount of time during which its medication release rate remains constant. Because of this, a significant amount of focus is presently being directed on the development of sustained-release tablets using matrix systems.

Since they have less negative consequences, natural polymers are often favored over synthetic ones in modern times.

Valsartan is a kind of drug that is classified as a BCS-II drug. It is an angiotensin II receptor antagonist, and it is often administered to patients suffering from high blood pressure or heart failure. It achieves its action by selectively inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. This is accomplished by preventing the binding of angiotensin II and angiotensin I receptors in a variety of tissues [56-60].

MATERIAL AND METHODS:

Materials-

Pectin powder, Guar gum, Starch, Magnesium sterate and Sucrose were obtained from local market. Valsartan was obtained as a gift from MATS School of Pharmacy, MAS University, Aarang-Kharora Highway, Gullu, Arang, Raipur, Chhattisgarh, India.

Methods-

As a result of the use of natural polymers with various percentages of guar gum and pectin (1:0.5, 1:1, and 1:1.5, respectively), the formulation of Valsartan S.R. tablets has been processed using the direct compression technique. This has led to the exploitation of natural polymers. Prior to putting the components through sieve no. 10 and subjecting them to various post-compression inspections, we assigned each component a specific weight that accurately represented its own weight. This action started the series of examinations. For a length of time that might last up to twenty-four hours, an *in-vitro* dissolving study was carried out at a speed of 785 revolutions per minute, with a pH of 7.4 and 0.1 N hydrochloric acid to be used as the solvent. To explore the rate at which the drug was released, this was done for the goal of this. In addition to the FTIR spectra of the purified active pharmaceutical ingredient (Fig.3), a calibration curve was developed with a pH of 7.4 and 0.1 N hypochlorous acid (Fig.1, Fig.2). Each formulation contained thirty milligrams of valsartan, and the total weight of the manufactured product was one hundred fifty milligrams. Table 1 provides detailed information on this. [61].




Fig.1: Calibration Curve of Valsartan Using 0.1N Hcl




Fig 2: Calibration Curve of Valsartan Using pH 7.4




Fig. 3: FTIR Spectra of Pure Drug

Table-1: Formulation Table

Sl no	Ingredients	FG1 (mg)	FG2 (mg)	FG3 (mg)	FP4 (mg)	FP5 (mg)	FP6 (mg)
1	Valsartan	30	30	30	30	30	30
2	Pectin	-----	-----	-----	15	30	45
3	Guargum	15	30	45	-----	-----	-----
4	Mg sterate	2%	2%	2%	2%	2%	2%
5	Sucrose	101	86	71	101	86	71
6	Starch	3%	3%	3%	3%	3%	3%
	Total weight	150 mg	150 mg	150 mg	150 mg	150 mg	150 mg

RESULTS:

A large number of post-compression experiments were carried out, and each and every one of them arrived at the same conclusion: the limit that was established in Table 2 was not met. The *in-vitro* drug release activities of each of the several formulations are broken down in unambiguous detail in Fig. 4, which may be seen here.

Table-2: Evaluation Parameters

Sl no	Parameter	FG1	FG2	FG3	FP4	FP5	FP6
1	Hardness(kg/cm ²)	5.4	5.4	5.4	5.4	5.4	5.3
2	Swelling index(%)	0.023	0.036	0.052	0.023	0.041	0.062
3	Weight variation (%)	1.26±0.22	1.29±0.23	1.31±0.23	1.24±0.23	1.28±0.21	1.28±0.23
4	Drug content (%)	96	97.2	98.1	92.3	94.1	96.1

Table.3: Stability Data

Parameters	At initial day	After 30 days
Hardness (kg/cm ²)	5.0±0.42	4.8±0.14
Thickness (mm)	3.52±0.64	3.52±0.11
Weight variation (mg)	400.04±4.87	399±0.78
Drug content (%)	101.01±0.2	99.97±0.7




Fig.4: In-vitro Drug Release Research

DISCUSSION:

As compared to other formulations, it was discovered that FG3 allowed for a maximum drug release of 94.5 percent in only 23 hours, making it a preferable choice. So, further research has to be carried out or explored, and formulations containing natural polymers need to be produced and introduced into the market in order to lessen the severity of the adverse effects[62-68].

Acknowledgement:

Authors are thankful to MATS School of Pharmacy, MATS University, Arang-Kharora highway, Gullu, Arang, Raipur, Chhattisgarh, India for their support. There was no ethical approval required for the research work.

Conflict of Interest: There is no conflict of interest.

REFERENCES:

1. Menon, T. V., & Sajeeth, C. I. (2013). Formulation and evaluation of sustained release sodium alginate microbeads of carvedilol. *Research Journal of Pharmacy and Technology*, 6(4), 392-397.
2. Bangale, G. S., Rathinaraj, S. B., Shinde, G. V., Umalkar, D. G., & Rajesh, K. S. (2011). Formulation and evaluation of natural gum based matrix tablets for oral controlled delivery of nimodipine. *Indian Journal of Pharmaceutical Education and Research*, 45(4), 375-383.
3. Fu, Q., Su, X., Hou, Y., Li, M., Li, J., Sun, J., & He, Z. (2016). Once-daily amoxicillin immediate-and extended-release bilayer tablets. *Powder Technology*, 301, 405-411.
4. Alkrad, J. A., Shmeis, R. A., Alshwabkeh, I., Abazid, H., & Mohammad, M. A. (2017). Investigation of the potential application of sodium bentonite as an excipient in formulation of sustained release tablets. *Asian journal of pharmaceutical sciences*, 12(3), 259-265.
5. Varsha, B. K., Bhutkar, M. A., Kumbhar, A. P., Pol, S. K., & Katare, P. B. (2013). Formulation and evaluation of sustained release matrix tablets of Pregabalin. *Research Journal of Pharmacy and Technology*, 6(11), 1190-1194.
6. Balan, G., Timmins, P., Greene, D. S., & Marathe, P. H. (2001). In vitro–in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. *Journal of pharmaceutical sciences*, 90(8), 1176-1185.
7. Hasan, A. A., Madkor, H., & Wageh, S. (2013). Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. *Drug delivery*, 20(3-4), 120-126.
8. Wadher, K. J., Kakde, R. B., & Umekar, M. J. (2011). Formulation of sustained release metformin hydrochloride matrix tablets: Influence of hydrophilic polymers on the release rate and in vitro evaluation. *International Journal of Research in Controlled Release*, 1(1), 9-16.
9. Roy, H., Brahma, C. K., Nandi, S., & Parida, K. R. (2013). Formulation and design of sustained release matrix tablets of metformin hydrochloride: Influence of hypromellose and polyacrylate polymers. *International Journal of Applied and Basic Medical Research*, 3(1), 55-63.
10. Patel, M. R., Patel, A. A., Prajapati, L. M., & Patel, N. M. (2012). Intragastric floating drug delivery system of metformin hydrochloride as sustained release component and glimepiride as immediate release component: formulation and evaluation. *International Journal of Pharmacy and Pharmaceutical sciences*, 4.

11. Varia, U., Prajapati, B., & Katariya, H. (2018). Formulation and development of bosentan loaded once a daily tablet for pulmonary artery hypertension using lipid matrices by 3 (2) full factorial design. *International journal of pharmaceutical sciences and research*, 9(11), 4729-4740.
12. Kancharla, S., Kolli, P., & Gopaiah, K. V. (2021). Nanosuspension formulation & evaluation of ritonavir & valsartan by using poloxamer as a stabilizing agent to enhance the oral bio availability. *International Journal of Health Care and Biological Sciences*, 04-17.
13. Kulkarni, G. S., Chaudhary, P. P., & Swamy, S. (2017). Formulation and evaluation of sustained release floating tablets of an antihypertensive diltiazem. *International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN)*, 10(5), 3844-3852.
14. Singh, K., Gupta, J. K., Shrivastava, A., Jain, D., Yadav, A. P., Dwivedi, S., Dubey, A., & Kumar, S. (2024). Exploring the Pharmacological Effects of Bioactive Peptides on Human Nervous Disorders: A Comprehensive Review. *CNS & neurological disorders drug targets*, <https://doi.org/10.2174/0118715273316382240807120241>.
15. Batt, A., Singh, K., Gupta, J. K., Chanchal, D. K., Kumar, K., Dubey, A., Jain, D. (2024). A comprehensive review of cellular stress response pathway system of *Rhizoma coptidis*. *Pharmacological Research - Modern Chinese Medicine*, 100491. <https://doi.org/10.1016/j.prmcm.2024.100491>
16. Kumar, A., Chaudhary, J. S., Dubey, A., & Pachorkar, S. S. (2024). Nanotechnology in Ankylosing Spondylitis: Advancements in Drug Delivery and Targeted Therapy. *International Journal of Drug Delivery Technology*, 14(2), 1162-1173.
17. Kumar, P., Savita, K. K., Dubey, A., & Gaur, S. S. (2024). Unlocking Dithranol's Potential: Advanced Drug Delivery Systems for Improved Pharmacokinetics. *International Journal of Drug Delivery Technology*, 14(2), 1174-1180.
18. Sharma, D., Ruhil, B., Dubey, A., Jain, D., Bhatia, D., & Koubouris, G. (2024). Unlocking Rapid and User-Friendly Strategies to Improve Horticultural Crop Qualities. *Horticulturae*, 10(8), 779. <https://doi.org/10.3390/horticulturae10080779>.
19. Dubey, A., Ansari M.V., Sahu, V. K., Mishra, A. (2024). Assessment of in-vitro Antimicrobial and Antioxidant Activity of Essential oil obtained from *Artemisia Argyi*. *Cahiers Magellanes-NS*, 6(2), 2961-2975. <https://magellanes.com/index.php/CMN/article/view/554>.
20. Anubhav, D., Mamta, K., Kumar, S. A., Swamy, S. K., & Manu, D. (2024). Global warming and its consequences for neurological disorders. *Disaster Advances*, 17(8), 30-40. <https://doi.org/10.25303/178da030040>.
21. Arora, S., Dubey, A., Kumari, M. (2024). The role of 3- D printing technologies. *Int J Pharm Chem Anal*, 11(2), 112-120. <https://doi.org/10.18231/j.ijpca.2024.016>.
22. Dubey, A., Kumari, M., & Kumar, V. (2024). In-vivo antidiabetic activity of asparagus racemosus seeds in streptozotocin induced diabetic model. *System*, 2(3), 146-152. <https://doi.org/10.55522/ijti.V2i3.0037>.
23. Dubey, A., Shukla, S., & Singh, D. (2024). Formulation and Evaluation of Antiviral Agent Loaded Polymeric Nanoparticles. *International Journal of Therapeutic Innovation*, 2(3), 163-169. <https://doi.org/10.55522/ijti.V2i3.0052>.
24. Gautam, M. K., Panda, P. K., Dubey, A., Kumari, M., & Ghosh, N. S. (2024). Zebrafish as a Fascinating Animal Model: A Robust Platform for in vivo Screening for Biomedical Research. *Int. J. Pharm. Investigation*, 14(3), 696-701.
25. Shukla, D., Tripathi, A. K., Pandey, S., Kumari, M., Dwivedi, M., & Dubey, A. (2024). A Systematic Study on Social-Environmental Risk Variables for Bacterial and Viral Conjunctivitis. *Revista Electronica de Veterinaria*, 25(1S), 220-228. <https://www.veterinaria.org/index.php/REDVET/article/view/605>
26. Dubey, A., Samra., Sahu, V. K., & Mishra, A. (2024). In Vitro Assessment of Antioxidants and Hepatoprotective Activity of *Opilia Celtidifolia*. *Afr.J.Bio.Sc.*, 6(7), 2705-2724.
27. Dwivedi S., Bais, N., Chhabra, G., Joshi, D., Jadhav, S. A., Dubey, A., Chhajer, M. (2024). Investigation of Antiulcer Activity of *Leonotis nepetaefolia* (L.) R.Br. in Pylorus ligation induced and Ethanol induced Gastric ulcer in rats. *Afr.J.Bio.Sc.*, 6(4), 446-451. <https://doi.org/10.33472/AFJBS.6.4.2024.231-240>
28. Kumari, M., Mishra, G., Shukla, D., Dwivedi, M., Ghosh, N., Tripathi, A.K., Dubey, A. (2024). A Novel scientific Approach: Zebrafish as an Informative in-vivo testing platform in Physiological Investigation. *Afr.J.Bio.Sc.*, 6(4), 231-240. <https://doi.org/10.33472/AFJBS.6.4.2024.231-240>
29. Dubey, A., Sharma, S., Kaur, G., Goel, V., Ghildiyal, M., & Kumari, M. (2024). A Systemic Education Of Therapeutic Approaches Using Native Herbs To Treat Rheumatoid Joint

- Dysfunction. *Educational Administration: Theory and Practice*, 30(5), 67-83. <https://doi.org/10.53555/kuey.v30i4.2774>
30. Gautam, M. K., Panda, P. K., Dubey, A., Kumari, M., & Ghosh, N. S. (2024). Zebrafish as a fascinating animal model: a robust platform for in vivo screening for biomedical researches. *International Journal of Agricultural Sciences and Veterinary Medicine*, 12(1), 173-187. <https://doi.org/10.25303/1201ijasvm034039>
31. Dubey, A., Samra, S. V., Dash, S. L., & Mishra, A. (2024). A review on plant *Opilia celtidifolia*: an assessment of its botany, conventional utilization, phytochemistry and pharmacology. *Int J Pharm Sci & Res*, 15(3), 690-98. <https://doi.org/10.13040/IJPSR.0975-8232>
32. Ansari, M. V., Dash, S. L., Sahu, V. K., Dubey, A., & Singh Rathor, V. P. (2024). An Update on the Chemical Composition and Pharmacological Profiles of *Artemisia* species. *Alinteri Journal of Agriculture Sciences*, 39(2), 67-87. <http://dergipark.gov.tr/alinterizbd>
33. Dubey, A., Kumari, M., & Pandey, M. (2024). Homeopathic Medicinal Products and Importance in Diabetes. *International Journal of Homeopathy & Natural Medicines*, 10(1), 17-26. <https://doi.org/10.11648/j.ijhnm.20241001.12>
34. Dwivedi, S., Chandekar, A., Tripathi, A., Mishra, R., Chhajed, M., Sharma, K., & Dubey, A. (2024). In-Vivo Anti-diabetic activity of *Leonotis nepetaefolia* (L.) R. Br. Root in Alloxan induced Diabetic Model. *Naturalista Campano*, 28(1), 2190-2193. <https://museonaturalistico.it>
35. Dubey, A., Ghosh, N. S., & Singh, R. (2023). An in-depth and in vitro evaluation of the antioxidant and neuroprotective activity of aqueous and ethanolic extract of *Asparagus racemosus* Linn seed. *Research Journal of Chemistry and Environment*, 27(10), 45-66. <https://doi.org/10.25303/2710rjce046066>
36. Kumari, M., Dubey, A., Agarwal, S., Kushwaha, S., & Sachan, A. K. (2023). Recent Technology and Software for GDP in the Pharmaceutical Industry. *International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN)*, 16(5), 7004-7007. <https://doi.org/10.37285/ijpsn.2023.16.5.9>
37. Dubey, A., Ghosh, N. S., & Singh, R. S. (2023). Effects of aqueous and ethanolic seed extract of *Asparagus racemosus* Linn on neurobehavioral pattern of acrylamide induced experimental Zebra fish. *Research Journal of Biotechnology*, 18(11), 81-88. <https://doi.org/10.25303/1811rjbt081088>
38. Dubey, A., Ghosh, N. S., Singh, R., & Bhattacharjee, C. (2023). Role of Aqueous and Ethanolic Seed Extract of *Asparagus racemosus* on Acr-Induced Neurotoxicity in Adult Zebrafish: Emergence of Neuroprotective Results. *Egyptian Journal of Aquatic Biology & Fisheries*, 27(6), 285-296. <https://doi.org/10.21608/EJABF.2023.329192>
39. Dubey, A., Ghosh, N. S., & Singh, R.S., (2023). A Toxicological Study on Seed Extracts of *Asparagus Racemosus* Linn (Ethanolic and Water) in Experimental Animals. *Journal of Advanced Zoology*, 44(2), 71–78. <https://doi.org/10.17762/jaz.v44i2.194>
40. Anubhav, D., Mrinmoy, B., Biplab, D., & Niladry, G. (2023). Queen of all herbs (*Asparagus racemosus*): an assessment of its botany, conventional utilization, phytochemistry and pharmacology. *Research Journal of Biotechnology*, 18(6), 146-154. <https://doi.org/10.25303/1806rjbt1460154>
41. Dash, S. L., Gupta, P., Dubey, A., Sahu, V. K., & Mishra, A. (2023). An Experimental Models (In-Vivo and In-Vitro) Used for the Study of Antidiabetic agents. *Journal of Advanced Zoology*, 44(4), 86–95. <https://doi.org/10.17762/jaz.v44i4.1461>
42. Dubey, A., Ghosh, N. S., & Singh Karuna, V. P. (2023). Hematological and hypolipidemic effects of methanol extract of *oldenandia corymbosa* (rubiaceous) seeds in streptozotocin (stz) diabetic in wistar rats. *A Journal for New Zealand Herpetology*, 12(3), 2203-2210. <http://biogecko.co.nz/.2023.v12.i03.pp2309-2317>
43. Dubey, A., Pandey, M., Yadav, S., Tripathi, D., Kumari, M., & Purohit, D. (2023). Hypolipidemic and haematological effects of ethanolic extract of *Tecoma stans* linn (bignoniaceae) seeds in alloxan-induced diabetic albino rats. *Korean Journal of Physiology and Pharmacology*, 27(1), 85-90. <https://doi.org/10.25463/kjpp.27.1.2023.8>
44. Dubey, A., Dash, S. L., Kumari, M., Patel, S., Singh, S., & Agarwal, S. (2023). A Comprehensive Review on Recent Progress in In vivo and In vitro Models for Hyperlipidemia Studies. *Pakistan Heart Journal*, 56(1), 286-297.
45. Dubey, A., Sahu, V. K., Dash, S. L., & Mishra, A. (2023). A Screening Models of (In Vivo And In Vitro) Used for the Study of Hepatoprotective Agents. *Journal of Advanced Zoology*, 44(3), 173–187. <https://doi.org/10.17762/jaz.v44i3.578>

46. Dubey, A., Ghosh, N. S., Gupta, A., & Singh, S. (2023). A review on current epidemiology and molecular studies of lumpy skin disease virus-an emerging worldwide threat to domestic animals. *Journal of medical pharmaceutical and allied sciences*, 12(1), 5635–5643. <https://doi.org/10.55522/jmpas.V12I1.4583>
47. Patel, S., Dubey, A., Gupta, A. K., & Ghosh, N. S. (2023). Evaluation of Antimicrobial Activity of Calotropis Gigantea Extracts on Two Main Skin Infection Causing Bacteria - Escherichia Coli and Staphylococcus Aureus. *International Journal of Food and Nutritional Sciences*, 12(1), 145-157.
48. Mishra, T., Dash, S. L., Dubey, A., & Sahu, V. K. (2023). Phytochemical and antimicrobial activity study of different extracts of citrus medica l. leaf against some bacteria. *Eur. Chem. Bull*, 12(Special Issue 1), 587-596.
49. Dubey, A., Ghosh, N. S., & Singh, R. (2022). Zebrafish as An Emerging Model: An Important Testing Platform for Biomedical Science. *Journal of Pharmaceutical Negative Results*, 13(3), 1-7. <https://doi.org/10.47750/pnr.2022.13.03.001>.
50. Anubhav Dubey, Raghuvendra Singh, Ashish Kumar, Gaurav Mishra, Anubha Gupta, Anuj Sonker, & Amit Mishra. (2022). A Critical Review on Changing Epidemiology of Human Monkeypox-A Current Threat with Multi-Country Outbreak. *Journal of Pharmaceutical Negative Results*, 660–671. <https://doi.org/10.47750/pnr.2022.13.S01.82>
51. Dubey, A., Ghosh, N. S., Agnihotri, N., Kumar, A., Pandey, M., & Nishad, S. (2022). Herbs Derived Bioactive Compounds and their Potential for the Treatment of Neurological Disorders. *Clinical Schizophrenia & Related Psychoses*, 16(2). <https://doi.org/10.3371/CSRP.DANG.081922>
52. Dubey, A., Ghosh, N., Saxena, G. K., Purohit, D., Patel, S., & Singh, S. (2022). Management Implications for Neurotoxic Effects Associated with Antibiotic Use. *NeuroQuantology*, 20(6), 304-328. <https://doi.org/10.14704/nq.2022.20.6.NQ22034>
53. Dubey, A., Ghosh, N. S., Rathor, V. P. S., Patel, S., Patel, B., & Purohit, D. (2022). Sars- COV-2 infection leads to neurodegenerative or neuropsychiatric diseases. *International Journal of Health Sciences*, 6(S3), 2184-2197. <https://doi.org/10.53730/ijhs.v6nS3.5980>
54. Meher, C. P., Purohit, D., Kumar, A., Singh, R., & Dubey, A. (2022). An updated review on morpholine derivatives with their pharmacological actions. *International Journal of Health Sciences*, 6(S3), 2218-2249. <https://doi.org/10.53730/ijhs.v6nS3.5983>.
55. Patnaik, S., Purohit, D., Biswasroy, P., Diab, W. M., & Dubey, A. (2022). Recent advances for comedonal acne treatment by employing lipid nanocarriers topically. *International Journal of Health Sciences*, 6(S8), 180-205. <https://doi.org/10.53730/ijhs.v6nS8.9671>
56. Srivastav, G., Gupta, D., Dubey, A., & Kumar, N. (2022). Investigation of Anti-Pyretic Activity of Cinnamon Oil in Wistar Rat. *Journal for Research in Applied Sciences and Biotechnology*, 1(3), 51-56. <https://doi.org/10.55544/jrasb.1.3.7>
57. Panda, B. B., Patnaik, S., Purohit, D., Das, S., & Dubey, A. (2022). Impact of sodium starch glycolate on Physico-chemical characteristics of mouth dissolving film of Fexofenadine. *NeuroQuantology*, 20(6), 7604-7613. <https://doi.org/10.14704/nq.2022.20.6.NQ22759>
58. Singh, S., Dwivedi, J., Tripathi, D., Verma, P., Ghosh, N. S., & Dubey, A. (2022). Nanorobots is an Emerging Technology applicable in the Diagnosis and Treatment of Neuronal and Various Disease. *NeuroQuantology*, 6(20), 1081-1096. <https://doi.org/10.14704/nq.2022.20.6.NQ2210>
59. Kumari, P., Kumar, S., Shukla, B. P., Dubey, A. (2021). An overview on breast cancer. *International Journal of Medical and all body Health Research*, 2(3), 59-65.
60. Yadav, P., & Dubey, A. (2021). Formulation and characterization of anti-epileptic drug transdermal patch for enhance skin permeation. *European Journal of Biomedical*, 8(9), 784-790
61. Prerna, D. A., & Ratan, G. (2021). Nanoparticles: An Overview. *Drugs and Cell Therapies in Haematology*, 10(1), 1487-1497.
62. Dubey, A., Tiwari, M., Kumar, V., Srivastava, K., & Singh, A. (2020). Investigation of Anti-Hyperlipidemic Activity of Vinpocetine in Wistar Rat. *International Journal of Pharmaceutical Research*, 12(02), 1879-1882. <https://doi.org/10.31838/ijpr/2020.12.02.250>
63. Raj Pratap Singh , Dr. Vishal Dubey ,Anubhav Dubey & Dr. Shantanu, Liposomal gels for vaginal drug delivery of Amoxicillin Trihydrate, *International Journal of Medical Research and Pharmaceutical Sciences*;2020 7(8) 1-13.
64. Kumar, N., Dubey, A., Mishra, A., & Tiwari, P. (2020). Ethosomes: A Novel Approach in Transdermal Drug Delivery System. *International Journal of Pharmacy & Life Sciences*, 11(5).
65. Srivastava, K., Dubey, A., Tiwari, M., & Dubey, A. (2020). To evaluate the synergistic effect of Pinitol with Glimepiride in diabetic Wistar rats. *J. Crit. Rev*, 7(13), 2058-2062.

66. Srivastava, K., Tiwari, M., & Dubey, A. D-Pinitol - A Natural Phytomolecule and its Pharmacological effect. *Int. J. of Pharm. & Life Sci.*, 11(5), 6609-6623.
67. Dubey, A., Tiwari, D., Srivastava, K., Prakash, O., & Kushwaha, R. (2020). A discussion on vinca plant. *Journal of Pharmacognosy and Phytochemistry*, 9(5), 27-31.
68. Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A Review on Diabetes Mellitus: Type1 & Type2. *World Journal of Pharmacy and Pharmaceutical Sciences*, 9(10), 838-850.